ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Hypertriglyceridemia results from accumulation of triglyceride (TG)-rich lipoproteins (TRLs) in the circulation and is associated with increased CVD risk. ApoC-III is an apolipoprotein on TRLs and a prominent negative regulator of TG catabolism. We recently established that in vivo apoC-III predominantly inhibits LDL receptor-mediated and LDL receptor-related protein 1-mediated hepatic TRL clearance and that apoC-III-enriched TRLs are preferentially cleared by syndecan-1 (SDC1). In this study, we determined the impact of apoE, a common ligand for all three receptors, on apoC-III metabolism using apoC-III antisense oligonucleotide (ASO) treatment in mice lacking apoE and functional SDC1 ( Apoe −/− Ndst1 f/f Alb-Cre + ). ApoC-III ASO treatment significantly reduced plasma TG levels in Apoe −/− Ndst1 f/f Alb-Cre + mice without reducing hepatic VLDL production or improving hepatic TRL clearance. Further analysis revealed that apoC-III ASO treatment lowered plasma TGs in Apoe −/− Ndst1 f/f Alb-Cre + mice, which was associated with increased LPL activity in white adipose tissue in the fed state. Finally, clinical data confirmed that ASO-mediated lowering of APOC-III via volanesorsen can reduce plasma TG levels independent of the APOE isoform genotype. Our data indicate that apoE determines the metabolic impact of apoC-III as we establish that apoE is essential to mediate inhibition of TRL clearance by apoC-III and that, in the absence of functional apoE, apoC-III inhibits tissue LPL activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3. ApoC-III ASO treatment does not affect hepatic VLDL production and TRL clearance in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were on apoC-III ASO or control (Ctrl) ASO for 4 weeks. Fasted mice (5 h) were given a 250 μl bolus of corn oil by oral gavage to measure fat tolerance. Postprandial TG levels were measured 0, 1, 2, and 3 h after gavage (n = 3 per group). B: Hepatic VLDL production was determined after intravenous injection of Tyloxapol (0.5 mg/g bodyweight) to block lipase activity. TRL uptake and plasma TG levels were measured at the indicated time points (n = 3–5 per group). C: Intestinal lipid absorption was analyzed by intravenous injection of Tyloxapol followed by oral gavage of corn oil (250 μl). Plasma TG levels were measured at the indicated time points (n = 3). D: Hepatic TRL clearance was analyzed by retinyl ester excursion. [3H]retinol (5 μCi) in 250 μl corn oil was orally gavaged and the remaining counts in the plasma were determined by liquid scintillation counting after 2, 4, 6, and 8 h (n = 3). E: Schematic overview of [3H]TRL clearance experiments in vivo. F: Isolated [3H]TRLs enriched (control ASO) or depleted (apoC-III ASO) in apoC-III were injected intravenously into Apoe−/−Ndst1f/fAlb-Cre+ mice on apoC-III ASO (n = 2). Clearance of [3H]TRLs was assessed by measuring the counts remaining in the plasma relative to the counts recovered 1 min after injection (values represent mean ± SEM; *P < 0.05, **P < 0.01).](https://figures.cochat.ai/paper-figures/b62465be48d4442b85400dd94637ff71/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-3.jpg)
![Fig. 4. ApoC-III inhibition of TRL clearance requires apoE. A–D: Primary hepatocytes were isolated from Apoe−/−Ndst1f/fAlb-Cre+ mice and binding (4°C) and uptake (37°C) of [3H]retinol-labeled apoC-III-enriched and apoC-III-deficient TRL particles were analyzed. A: Binding of [3H]TRLs (100 μg/ml) enriched or deficient in apoC-III was determined after incubation in primary hepatocytes in the absence or presence of apoE at 4°C for 1 h. Binding and uptake was assessed after incubation of [3H]retinol-labeled TRLs at 37°C for 4 h in a dose-dependent manner (10/20/50/100 μg/ml) in the absence (B) and presence (C) of apoE. D: Reconstituted [3H]TRLs (50 μg) were evaluated in their binding and uptake capacity in primary hepatocytes (n = 3 per condition in all experiments, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).](https://figures.cochat.ai/paper-figures/859203abd70f4aebaf61c58617c5f3d8/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-4.jpg)
![Fig. 5. ApoC-III lowering increased FA uptake in liver and WAT in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were fasted for 5 h. After a 5 min intravenous injection of [3H]triolein-labeled liposyn particles (100 μl), blood and the indicated tissues were harvested (A) and (B) tissue weights were determined (B). [3H]triolein tissue uptake was determined of the homogenized tissues by liquid scintillation counting (n = 4–6). C: [3H]palmitic acid uptake into various tissues of control (Ctrl) ASO- and apoC-III ASO-treated mice was analyzed by retro-orbital injection of 1 μCi (n = 4–6). D: Primary hepatocytes were isolated from mice administered with control ASO or apoC-III ASO and binding and uptake of [14C]oleic acid was assessed in vitro. Hepatocytes were incubated with 0.5 μCi of radiolabeled FAs at 37°C, and incorporation was measured at the indicated time points (n = 3 per condition; values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).](https://figures.cochat.ai/paper-figures/c1934e49e30648f198cede15faaacf0b/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-5.jpg)
![Fig. 6. Transcriptomics and metabolomics of hepatocytes from apoC-III ASO-treated Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Volcano-plot depicting a differential gene expression derived from RNA-seq analysis of livers isolated from fasted Apoe−/−Ndst1f/fAlb-Cre+ mice receiving apoC-III ASO or control (Ctrl) ASO for 8 weeks. Genes that were significantly (adjusted P < 0.05) up- or downregulated upon apoC-III ASO are highlighted (excluding Apoc3). B: A heat map showing differentially expressed protein-coding genes with adjusted P-value <0.05 upon apoC-III ASO (left panel, n = 5) compared with control ASO (right panel, n = 4). Heat maps of genes involved in de novo lipogenesis (C) and FA transport (D). E: ApoC-III ASO or control ASO were administered to Apoe−/−Ndst1f/fAlb-Cre+ mice and primary hepatocytes were isolated and incubated with 20 μM U-[13C16]palmitic acid tracer for 1 h and 4 h at 37°C for cellular FA metabolism analysis. After lipid extraction and GC/MS, enrichment of FA from U-[13C16]palmitic acid tracer and total FA composition were determined. F: Total percentage of C16:0 is shown. G: Enrichment of U-[13C16]palmitic acid tracer in metabolites of the TCA cycle (n = 3–4 per condition, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).](https://figures.cochat.ai/paper-figures/31eb247d13f241659476aed90ccc16fb/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-6.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Which factors determine the fate of a remnant particle (in the VLDL or IDL density range) remains incompletely defined, although apoCIII inhibits whereas apoE and possibly HL facilitate hepatic remnant uptake.74,75”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [75]
Experimental — accuracy not yet measuredIn the citing paper
“In mice, apoCIII impacts plasma TG levels and remnant accumulation when LpL activity is reduced, but not when normal.75”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“DESeq2 (34) was used to calculate differential gene expression based on uniquely aligned reads, and P-values were adjusted for multiple hypothesis testing with the BenjaminiHochberg method.”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“The spliced read aligner STAR (32) was used to align sequencing reads to the mouse GRCm38 genome.”
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 1×
“Polar metabolites and FAs were extracted using methanol/ water/chloroform and analyzed as previously described (35).”
Self-citationChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071 · cited 1×
“The importance of apoC-III in humans was established by the findings that inactivating mutations were shown to correlate with lower plasma TGs (15) and to protect against CVD (16–18).”
Identification of multiple subclasses of plasma low density lipoproteins in normal humans.
Krauss, R. M., & Burke, D. J. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38178-5 · Cited by 992
Self-citationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837 · cited 6×
“synthesized and secreted primarily by liver, brain, skin, and macrophages (11).”
InfluentialPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 4×
“More importantly, it needs to be determined whether the distinctly different TG clearance pathways modulated by APOC-III have a differential impact on CVD and longevity, which are associated with altered plasma apoC-III levels in the human population.”
Influential
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“In a mouse model, the effect of reducing apoCIII on hepatic remnant removal was significant only when LpL activity was markedly reduced, 75 possibly explaining the lack of apoB reduction with an apoCIII ASO in moderate hypertriglyceridaemia.”
BackgroundMetabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“Next to the well-established inhibition of LPL and thus attenuation of peripheral TRL disposal conferred by APOC3 [4,132,133], stimulation of VLDL secretion and inhibition of remnant endocytosis have been reported as APOC3 effects in the liver [132,134,135].”
BackgroundThe Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“It appears that apoC-III can inhibit hepatic clearance of remnants by LPL-independent pathways (Figure 1) (69), possibly by interfering with the binding of apoB and apoE to hepatic lipoprotein receptors including HSPG, LDLR and LRPl (31, 70).”
BackgroundMethodInfluentialAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“However, APOC3 deficiency or inhibition lowers TG levels in the absence of APOE likely as result of increased LPL activity and uptake of fatty acids in adipose tissue (92).”
BackgroundRegulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114
“[18] determined the role of ApoE in ApoC3’s action on hepatic clearance of TRL via syndecan 1 (SDC1).”
Background
Metadata
- Authors
- Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., Benner, C., Alexander, V. J., Witztum, J. L., Tsimikas, S., Esko, J. D., & Gordts, P. L. S. M.
- Affiliations
- Bielefeld University (DE)
- University of California San Diego (US)
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Ramms, Bastian
- Gordts, Philip L.S.M.
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 60
- Issue
- 8
- Pages
- 1379-1395
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC6672034
- OpenAlex
- W2945419995
- Cited by
- 59
- References
- 64
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 6 · 2021: 12 · 2020: 11 · 2019: 6
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 384 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- American Heart Association (17PRE33410619, 15BGIA25550111)
- National Institute of General Medical Sciences (GM33063)
- National Heart, Lung, and Blood Institute (P01 HL107150)
- Ionis Pharmaceuticals, Inc.
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, lipoprotein lipase, triglyceride-rich lipoproteins, apolipoprotein E, syndecan-1, hypertriglyceridemia, volanesorsen, white adipose tissue, triglyceride catabolism, ApoE-deficient mice
- MeSH terms
- Mice, Knockout, ApoE, Animals, Apolipoproteins E, Lipoprotein Lipase, Receptors, LDL, Triglycerides, Mice, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. https://app.cochat.ai/papers/10.1194/jlr.m093740
- The paper
- Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., Benner, C., Alexander, V. J., Witztum, J. L., Tsimikas, S., Esko, J. D., & Gordts, P. L. S. M. (2019). ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. Journal of Lipid Research. https://doi.org/10.1194/jlr.m093740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.